Search research articles
Contact Us
Filters
Showing results (11-20 of 44) with videos related to
Page
of 5
Sort By:
Neuron
|
February 1, 2006
A role for Runx transcription factor signaling in dorsal root ganglion sensory neuron diversification
Ina Kramer, Markus Sigrist, Joriene C de Nooij, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2014
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels
Ming-Kang Chang, Ina Kramer, Thomas Huber, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
August 19, 2007
Control of the SOST bone enhancer by PTH using MEF2 transcription factors
Olivier Leupin, Ina Kramer, Nicole M Collette, et al.
Neuron
|
May 14, 2003
Peripheral NT3 signaling is required for ETS protein expression and central patterning of proprioceptive sensory afferents
Tushar D Patel, Ina Kramer, Jan Kucera, et al.
Journal of the Royal Society, Interface
|
April 20, 2018
<i>Sost</i> deficiency leads to reduced mechanical strains at the tibia midshaft in strain-matched <i>in vivo</i> loading experiments in mice
Laia Albiol, Myriam Cilla, David Pflanz, et al.
Genesis (New York, N.Y. : 2000)
|
November 8, 2007
Characterization of a thy1.2 GFP transgenic mouse reveals a tissue-specific organization of the spinal dorsal horn
Mino D Belle, Edward F Pattison, Ornsiri Cheunsuang, et al.
Bone
|
May 3, 2017
Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta
David G Little, Lauren Peacock, Kathy Mikulec, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 11, 2022
Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva
Thomas Ullrich, Luca Arista, Sven Weiler, et al.
Calcified Tissue International
|
May 31, 2018
Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume
Alyson Morse, Tegan L Cheng, Aaron Schindeler, et al.
Bone
|
October 28, 2009
Ubiquitous overexpression of Hey1 transcription factor leads to osteopenia and chondrocyte hypertrophy in bone
Rishard Salie, Michaela Kneissel, Mirko Vukevic, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 44) with videos related to
Sort By:
Page
of 5
Neuron
|
February 1, 2006
A role for Runx transcription factor signaling in dorsal root ganglion sensory neuron diversification
Ina Kramer, Markus Sigrist, Joriene C de Nooij, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2014
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels
Ming-Kang Chang, Ina Kramer, Thomas Huber, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
August 19, 2007
Control of the SOST bone enhancer by PTH using MEF2 transcription factors
Olivier Leupin, Ina Kramer, Nicole M Collette, et al.
Neuron
|
May 14, 2003
Peripheral NT3 signaling is required for ETS protein expression and central patterning of proprioceptive sensory afferents
Tushar D Patel, Ina Kramer, Jan Kucera, et al.
Journal of the Royal Society, Interface
|
April 20, 2018
<i>Sost</i> deficiency leads to reduced mechanical strains at the tibia midshaft in strain-matched <i>in vivo</i> loading experiments in mice
Laia Albiol, Myriam Cilla, David Pflanz, et al.
Genesis (New York, N.Y. : 2000)
|
November 8, 2007
Characterization of a thy1.2 GFP transgenic mouse reveals a tissue-specific organization of the spinal dorsal horn
Mino D Belle, Edward F Pattison, Ornsiri Cheunsuang, et al.
Bone
|
May 3, 2017
Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta
David G Little, Lauren Peacock, Kathy Mikulec, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 11, 2022
Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva
Thomas Ullrich, Luca Arista, Sven Weiler, et al.
Calcified Tissue International
|
May 31, 2018
Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume
Alyson Morse, Tegan L Cheng, Aaron Schindeler, et al.
Bone
|
October 28, 2009
Ubiquitous overexpression of Hey1 transcription factor leads to osteopenia and chondrocyte hypertrophy in bone
Rishard Salie, Michaela Kneissel, Mirko Vukevic, et al.
Page
of 5